Strengthen capacity of the South African Government?s Department of Health to provide quality and sustainable clinical care for HIV-infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretroviral
The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
02/26/2013
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
CDC-RFA-GH13-1335
Opportunity Category:
Discretionary
Posted Date:
Feb 26, 2013
Creation Date:
Feb 26, 2013
Original Closing Date for Applications:
Apr 15, 2013
Current Closing Date for Applications:
Apr 15, 2013
Archive Date:
May 15, 2013
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Health
Category Explanation:
Expected Number of Awards:
3
Estimated Total Program Funding:
$50,000,000
Award Ceiling:
$5,000,000
Award Floor:
$0
CFDA Number(s):
93.067
--
Global AIDS
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility:
ELIGIBILITY INFORMATION
Eligible Applicants
Eligible applicants that can apply for this funding opportunity are listed below:
Nonprofit with 501C3 IRS status (other than institution of higher education)
Nonprofit without 501C3 IRS status (other than institution of higher education)
For-profit organizations (other than small business)
Small, minority, and women-owned businesses
Universities
Colleges
Research institutions
Hospitals
Community-based organizations
Faith-based organizations
Federally recognized or state-recognized American Indian/Alaska Native tribal governments
American Indian/Alaska native tribally designated organizations
Alaska Native health corporations
Urban Indian health organizations
Tribal epidemiology centers
State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau)
Political subdivisions of States (in consultation with States)
Non-domestic (non-U.S.) entity
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov.
Agency Name
Centers for Disease Control and Prevention
Description
Under the leadership of the U.S. Global AIDS Coordinator, as part of the President's Emergency Plan, the U.S. Department of Health and Human Services Centers for Disease Control and Prevention (HHS/CDC) works with host countries and other key partners to assess the needs of each country and design a customized program of assistance that fits within the host nation's strategic plan and partnership framework.
HHS/CDC focuses primarily on two or three major program areas in each country. Goals and priorities include the following:
Achieving primary prevention of HIV infection through activities such as expanding confidential counseling and testing programs linked with evidence based behavioral change and building programs to reduce mother-to-child transmission;
Improving the care and treatment of HIV/AIDS, sexually transmitted infections (STIs) and related opportunistic infections by improving STI management; enhancing laboratory diagnostic capacity and the care and treatment of opportunistic infections; interventions for intercurrent diseases impacting HIV infected patients including tuberculosis (TB); and initiating programs to provide anti-retroviral therapy (ART);
Strengthening the capacity of countries to collect and use surveillance data and manage national HIV/AIDS programs by expanding HIV/STI/TB surveillance programs and strengthening laboratory support for surveillance, diagnosis, treatment, disease monitoring and HIV screening for blood safety; and
Developing, validating and/or evaluating public health programs to inform, improve and target appropriate interventions, as related to the prevention, care and treatment of HIV/AIDS, TB and opportunistic infections.
